title: Endotoxin and anti-endotoxin antibodies in the prognosis of acute pancreatitis.
abstract: OBJECTIVE
  We investigate the behaviour of endotoxin in patients with acute pancreatitis and its relationship with the development of complications.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  We assessed plasmatic endotoxin and anti-core endotoxin antibodies (EndoCab IgG and IgM) levels on first and third days from admission in patients with acute pancreatitis episodes, classifying them as mild or severe according to Atlanta's criteria.
  
  
  RESULTS
  Nineteen patients were included, seven with severe pancretitis (36.8%) and twelve with mild pancreatitis (63.2%). Endotoxin levels were similar on first day in both mild and severe pancreatitis, and higher in the latter on third day (p > 0.05). Patients with severe pancretitis had lower EndoCab IgM levels on first and third days from admission (day 1: 18.3 vs 33.3 MU/ml, p < 0.01; day 3: 18.4 vs 33.4 MU/ml, p < 0.05). When analysed separately systemic and local complications, we observed, in the same days, a decrease of EndoCab IgM levels in patients who developed systemic complications (day 1: 18.3 vs 32.7 MU/ml, p = 0.01; day 3: 18.3 vs 35.1 MU/ml, p < 0.01). EndoCab IgG levels were also lower in severe acute pancreatitis in both determinations, but differences weren't significant.
  
  
  CONCLUSIONS
  EndoCab levels decrease early in severe acute pancreatitis, mainly if systemic complications are present. This antibody depletion is greater for IgM than IgG, and seems to occur earlier than an increase in endotoxemia.
authors.affiliation: Department of Gastroenterology and Liver Unit, Hospital General Universitario, Alicante, Spain. jmsempere@coma.es
authors.forename: J
authors.initials: J
authors.lastname: Martínez
authors.forename: J M
authors.initials: JM
authors.lastname: Palazón
authors.forename: C
authors.initials: C
authors.lastname: Muñoz
authors.forename: M
authors.initials: M
authors.lastname: López
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Payá
authors.forename: R
authors.initials: R
authors.lastname: Laveda
authors.forename: M
authors.initials: M
authors.lastname: Pérez-Mateo
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000276:immunology*; D004731:Endotoxins / Q000097:blood* / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000097:blood* / Q000145:classification / Q000276:immunology*; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D000906:Antibodies; D004731:Endotoxins